The FDA is expected to decide on treatments for Alzheimer disease agitation, focal segmental glomerulosclerosis, hematological malignancies, HIV-1, and obesity.
The CWRU Quality Improvement Program (QIP) answers many of the frequently asked questions about registering studies on ClinicalTrials.gov. If your question isn’t addressed here, please email us at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results